Clinical trial Recruiting at 1 site Observational Ages 18 and up

Bleeding after oral soft tissue biopsy in people taking DOAC blood thinners

Official title: Bleeding Outcomes Following Oral Soft Tissue Biopsy in Patients Receiving Direct Oral Anticoagulants

Run by University of Pisa · NCT07520890 · Data updated 2026-11-12

This study will test whether continuing DOAC blood thinners is safe for people having an excisional oral soft tissue biopsy by comparing bleeding in 50 patients on uninterrupted DOACs with 50 patients not on anticoagulants.

More Minimally Invasive Surgical Procedures trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorUniversity of Pisa
Academic / other
Locations1 site (Pisa, Pi)
StatusRecruiting
StartedApril 1, 2026
Main results expectedMay 31, 2026
Study endsDecember 31, 2026
Registry record updatedApril 9, 2026
Trial IDNCT07520890 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults who need an excisional oral soft tissue biopsy, can provide informed consent, and either are taking a DOAC or are not on anticoagulants, without congenital or acquired coagulopathy and not on active antiplatelet therapy other than low‑dose aspirin.

Probably not a fit

Patients with known bleeding disorders, active non‑aspirin antiplatelet therapy, severe liver disease, or who require different or more extensive oral procedures may not benefit from the study's findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective case-control study at the Unit of Dentistry and Oral Surgery, University Hospital of Pisa, compares bleeding outcomes in 50 patients who continue DOAC therapy and 50 anticoagulant‑naive controls undergoing a standardized excisional oral soft tissue biopsy under local anesthesia with resorbable sutures. Bleeding will be recorded intraoperatively, at set perioperative timepoints up to 80 minutes, and by patient diary from postoperative days 1 through 7. Local haemostatic measures (tranexamic acid‑soaked gauze, resuturing, diathermocoagulation) will be applied as needed and DOACs will not be interrupted. The study aims to clarify whether continuing DOACs is safe for this specific oral surgical procedure.

Why it matters

Potential benefit: If successful, patients on DOACs may be able to continue their anticoagulant therapy for oral soft tissue biopsies, avoiding interruption and reducing thromboembolic risk while maintaining manageable bleeding control.

How similar studies have gone: Existing evidence on DOAC management for oral soft tissue biopsy is limited and mixed, so this prospective standardized comparison is relatively novel for this procedure.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* capacity to understand and sign informed consent;
* documented indication for oral soft tissue biopsy

Exclusion Criteria:

* inability to provide consent;
* congenital or acquired coagulopathy (including haemophilia, von Willebrand disease, thrombocytopenia, or hepatic cirrhosis);
* active antiplatelet therapy other than low-dose aspirin

Where it's running

  • University of Pisa
    Pisa, Pi, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.